Depressive symptoms are common in Alzheimer's disease (AD), leading to an increasing use of antidepressants.
Objective
To compare the effects of vortioxetine with other conventional antidepressants on cognition in AD patients with depressive symptoms.
Methods
This analysis is a subgroup of a 12-month, prospective, randomized, open-label, parallel-group study involving 108 outpatients receiving either vortioxetine or escitalopram, paroxetine, or bupropion as part of routine care. Data were collected at baseline, 6 and 12 months. Cognitive symptoms were assessed using the Mini-Mental State Examination (MMSE), Attentive Matrices (AM), Coloured Progressive Matrices (CPR), and Digit Span; depressive symptoms using the Hamilton Depression Scale (HAM-D) and the Cornell Scale for Depression in Dementia (CSDD). Results for patients on vortioxetine were compared to those on other antidepressants.
Results
Total scores on cognitive measures improved in all groups. Improvements versus baseline in MMSE, AM, and CPM were statistically significant in the vortioxetine group (p < 0.001), but not in the other antidepressant groups. Digit Span scores did not differ significantly from baseline. The between-group differences in MMSE, AM, and CPM changes were statistically significant in favor of vortioxetine (p < 0.05), while the Digit Span change showed a trend towards superiority with vortioxetine, but did not reach statistical significance. The between-group differences in HAM-D and CSDD changes were also statistically significant for vortioxetine (p < 0.05).
Conclusions
Vortioxetine was superior in improving both cognitive and depressive symptoms compared to other antidepressants. Larger studies which may also help to understand whether the beneficial effect observed with vortioxetine was a direct effect or mediated by its specific antidepressant efficacy are required.
WielsWBaekenCEngelborghsS. Depressive symptoms in the elderly – an early symptom of dementia? A systematic review. Front Pharmacol2020; 11: 34.
2.
StarksteinSEJorgeRMizrahiR, et al.The construct of minor and major depression in Alzheimer's disease. Am J Psychiatr2005; 162: 2086–2093.
3.
ArnaudAMBristerTSDuckworthK, et al.Impact of major depressive disorder on comorbidities: a systematic literature review. J Clin Psychiatry2022; 83: 21r14328.
4.
PuranenATaipaleHKoponenN, et al.Incidence of antidepressant use in community-dwelling persons with and without Alzheimer's disease: 13-year follow-up. Int J Geriatr Psychiatry2017; 32: 94–101.
5.
Vom HofeIStrickerBHVernooijMW, et al.Antidepressants use in relation to dementia risk, cognitive decline and brain atrophy. Alzheimers Dement2024; 20: 3378–3387.
6.
CirritoJRDisabatoBMRestivoJL, et al.Serotonin signaling is associated with lower amyloid-β levels and plaques in transgenic mice and humans. Proc Natl Acad Sci U S A2011; 108: 14968–14973.
7.
BartelsCWagnerMWolfsgruberS, et al.Impact of SSRI therapy on risk of conversion from mild cognitive impairment to Alzheimer’s dementia in individuals with previous depression. Am J Psychiatry2018; 175: 232–241.
8.
RaskinJWiltseCGSiegalA, et al.Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder:an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry2007; 164: 900–909.
9.
LavretskyHReinliebMSt CyrN, et al.Citalopram, methylphenidate, or their combination in geriatric depression: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry2015; 172: 561–569.
10.
LyketsosCGDelCampoLSteinbergM, et al.Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Arch Gen Psychiatry2003; 60: 737–746.
11.
DudasRMaloufRMcCleeryJ, et al.Antidepressants for treating depression in dementia. Cochrane Database Syst Rev2018; 8: CD003944.
12.
Bang-AndersenBRuhlandTJørgensenM, et al.Discovery of 1-[2-(2,4-dimethylphenylsulfanyl) phenyl]piperazine (lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem2011; 54: 3206–3221.
13.
MørkAPehrsonALBrennumLT, et al.Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. J Pharmacol Exp Ther2012; 340: 666–675.
14.
PehrsonALSanchezC. Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction. CNS Spectr2014; 19: 121–133.
15.
SanchezCAsinKEArtigasF. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacol Ther2015; 145: 43–47.
16.
DaleEZhangHLeiserSC, et al.Vortioxetine disinhibits pyramidal cell function and enhances synaptic plasticity in the rat hippocampus. J Psychopharmacol2014; 28: 891–902.
17.
du JardinKGJensenJBSanchezC, et al.Vortioxetine dosedependently reverses 5-HT depletion-induced deficits in spatial working and object recognition memory: a potential role for 5-HT1A receptor agonism and 5-HT3 receptor antagonism. Eur Neuropsychopharmacol2014; 24: 160–171.
18.
MørkAMontezinhoLPMillerS, et al.Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats. Pharmacol Biochem Behav2013; 105: 41–50.
19.
PehrsonALCremersTBétryC, et al.Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters—a rat microdialysis and electrophysiology study. Eur Neuropsychopharmacol2013; 23: 133–145.
20.
CumboECumboSTorregrossaS, et al.Treatment effects of vortioxetine on cognitive functions in mild Alzheimer’s disease patients with depressive symptoms: a 12 month, open-label, observational study. J Prev Alzheimers Dis2019; 6: 192–197.
21.
PadovaniACaratozzoloASBenussiA, et al.Vortioxetine treatment for depression in patients with prodromal vs mild Alzheimer’s disease: a six-month, open-label, observational study. J Prev Alzheimers Dis2024; 2: 375–381.
22.
CumboEAdairMÅstromDO, et al.Effectiveness of vortioxetine in patients with major depressive disorder and comorbid Alzheimer’s disease in routine clinical practice: an analysis of a post-marketing surveillance study in South Korea. Front Aging Neurosci2023; 14: 1037816.
23.
ValverdeAHCampilloJMGodinhoF. Vortioxetine use in demented patients. Alzheimers Dement2020; 16: e042132.
24.
ChristensenMCNitschky SchmidtS, et al.Effectiveness of vortioxetine in patients with major depressive disorder and early-stage dementia: the MEMORY study. J Affect Disord2023; 338: 423–431.
25.
TanSNTanC. Vortioxetine improves cognition in mild cognitive impairment. Int Clin Psychopharmacol2021; 36: 279–287.
26.
McKhannGMKnopmanDSChertkowH, et al.The diagnosis of dementia due to Alzheimer’s disease: recommendations from the national institute on aging and the Alzheimer’s association workgroup. Alzheimers Dement2011; 7: 263–269.
27.
FolsteinMFFolsteinSEMcHughPR. “Mini mental state” a practical method for grading the cognitive state of patients for the clinicians. J Psychiatr Res1975; 12: 189–198.
28.
SpinnlerHTognoniG and The Italian Group on the Neuropsychological Study of Aging. Italian Standardization and classification of neuropsychological tests. Ital J Neurol Sci1987; 8(Suppl 8): 1–120.
29.
RavenJC. Raven’s coloured progressive matrices. New York: Psychological Corporation, 1962.
30.
WechslerD. The Wechsler adult intelligence scale-revised (manual). New York: Psychological Corporation, 1981.
31.
HamiltonM. A rating scale for depression. J Neurol Neurosurg Psychiatry1960; 23: 56–62.
32.
AlexopoulosGSAbramsRCYoungRC, et al.Cornell scale for depression in dementia. Biol Psychiatry1988; 23: 271–284.
33.
HyttelJ.Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol1994; 9(Suppl 1): 19–26.
34.
LandesAMSperrySDStraussME. Prevalence of apathy, dysphoria and depression in relation to dementia severity in Alzheimer’s disease. J Neuropsychiatry Clin Neurosci2005; 17: 342–349.
35.
KatonaCHansenTOlsenCK. A randomized, double-blind, placebo- controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol2012; 27: 215–223.
36.
MahableshwarkarARZajeckaJJacobsonW, et al.A randomized, placebo- controlled, active-reference, double-blind, flexible-dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacology2015; 40: 2025–2037.
37.
ThompsonSHerrmannNRapoportMJ, et al.Efficacy and safety of antidepressants for treatment of depression in Alzheimer’s disease: a metaanalysis. Can J Psychiatry2007; 52: 248–255.
38.
MontgomerySANielsenRZPoulsenLH, et al.A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin–noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine. Hum Psychopharmacol Clin Exp2014; 29: 470–482.
39.
McIntyreRSLophavenSOlsenCK. A randomized, double-blind, placebo- controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol2014; 17: 1557–1567.
40.
VietaESluthLBOlsenCK. The effects of vortioxetine on cognitive dysfunction in patients with inadequate response to current antidepressants in major depressive disorder: a short-term, randomized, double-blind, exploratory study versus escitalopram. J Affect Disord2018; 227: 803–809.
41.
JeongHWYoonKHLeeCH, et al.Vortioxetine treatment for depression in Alzheimer’s disease: a randomized, double-blind, placebo-controlled study. Clin Psychopharmacol Neurosci2022; 20: 311–319.
42.
HarrisonJESøren LophavenSOlsenCK. Which cognitive domains are improved by treatment with vortioxetine?Int J Neuropsychopharmacol2016; 19: pyw054.
